ADVERSE DRUG REACTIONS IN CHILDREN


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Currently, adverse drug reactions (ADRs) are a big problem due to the high prevalence and the potential severity of their outcomes. There are type A (dose-dependent, more common) and type B (unpredictable, often more severe and clinically problematic) ADRs. The children’s population is more vulnerable to the development of ADRs due to the immaturity of the systems involved in the absorption, metabolism, transport and elimination of drugs, which should be taken into account during prescription of pharmacotherapy in children.

Palavras-chave

Texto integral

Acesso é fechado

Sobre autores

T. Eliseeva

FSBEI HE "Nizhny Novgorod State Medical Academy" of RMH

Email: eliseevati@yandex.ru
MD, Associate Professor at the Department of Hospital Pediatrics Nizhny Novgorod

E. Tush

FSBEI HE "Nizhny Novgorod State Medical Academy" of RMH

Nizhny Novgorod

I. Balabolkin

Scientific Center for Children's Health

Moscow

V. Bulgakova

Scientific Center for Children's Health

Moscow

N. Novikova

SBHCI NR "Children's City Clinical Hospital № 1"

Nizhny Novgorod

E. Zastelo

SBHCI NR "Children's City Clinical Hospital № 1"

Nizhny Novgorod

P. Trushanina

FSBEI HE "Nizhny Novgorod State Medical Academy" of RMH

Nizhny Novgorod

O. Khaletskaya

FSBEI HE "Nizhny Novgorod State Medical Academy" of RMH

Nizhny Novgorod

T. Potemina

FSBEI HE "Nizhny Novgorod State Medical Academy" of RMH

Nizhny Novgorod

Bibliografia

  1. Smyth R.M., Gargon E., Kirkham J., Cresswell L., Golder S., Smyth R., Williamson P. Adverse drug reactions in children- a systematic review. PLoS One. 2012;7(3):e24061.
  2. Dona I., Barrionuevo E., Blanca-Lopez N., Torres M.J., Fernandez T.D., Mayorga C., Canto G., Blanca M. Trends in hypersensitivity drug reactions: more drugs, more response patterns, more heterogeneity. J. Investig Allergol. Clin. Immunol. 2014;24(3):143-53.
  3. Kaufman G. Adverse drug reactions: classification, susceptibility and reporting. Nurs. Stand. 2016;30(50):53-63.
  4. Elzagallaai A.A., Greff M., Rieder M.J. Adverse Drug Reactions in Children: The Double-Edged Sword of Therapeutics. Clin. Pharmacol. Ther. 2017;101(6):725-35.
  5. Kearns G.L., Abdel-Rahman S.M., Alander S.W., Blowey D.L., Leeder J.S., Kauffman R.E. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 2003;349(12):1157-67.
  6. Miller R.P., Roberts R.J., Fischer L.J. Acetaminophen elimination kinetics in neonates, children, and adults. Clin. Pharmacol. Ther. 1976;19(3):284-94.
  7. van den Anker J.N., Hop W.C., de Groot R., van der Heijden B.J., Broerse H.M., Lindemans J., Sauer P.J. Effects of prenatal exposure to betamethasone and indomethacin on the glomerular filtration rate in the preterm infant. Pediatr. Res. 1994;36(5):578-81.
  8. Gell PG.H., Coombs R.R.A. The classification of allergic reactions underlying disease. In: Gell PG.H, editor. Clinical aspects of immunology. London ed: Blackwell Sci., 1963. p. 317-37.
  9. Castro-Pastrana L.I., Ghannadan R., Rieder M.J., Dahlke E., Hayden M., Carleton B. Cutaneous adverse drug reactions in children: an analysis of reports from the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). J. Popul. Ther. Clin. Pharmacol. 2011;18:106-20.
  10. Eliseeva T.I., Balabolkin I.I. Drug Allergic Reactions: Current Views (Review). Sovremennye tehnologii v medicine 2016;8(1):159-72.
  11. Star K., Noren G.N., Nordin K., Edwards I.R. Suspected adverse drug reactions reported for children worldwide: an exploratory study using Vigi Base. Drug. Saf. 2011;34(5):415-28.
  12. Limsuwan T., Demoly P. Acute symptoms of drug hypersensitivity (urticaria, angioedema, anaphylaxis, anaphylactic shock). Med. Clin. North. Am. 2010;94(4):691-710.
  13. Macy E. Practical Management of Patients with a History of Immediate Hypersensitivity to Common non-Beta-Lactam Drugs. Curr. Allergy Asthma Rep. 2016;16(1)4.
  14. Leach M.W., Rottman J.B., Hock M.B., Finco D., Rojko J.L., Beyer J.C. Immunogenicity/ hypersensitivity of biologics. Toxicol. Pathol. 2014;42(1):293-300.
  15. Pichler W.J., Adam J., Daubner B., Gentinetta T., Keller M., Yerly D. Drug hypersensitivity reactions: pathomechanism and clinical symptoms. Med. Clin. North. Am. 2010;94(4):645-64.
  16. Garratty G. Immune hemolytic anemia caused by drugs. Expert. Opin. Drug. Saf. 2012;11(4):635-42.
  17. Rojko J.L., Evans M.G., Price S.A., Han B., Waine G., DeWitte M., Haynes J., Freimark B., Martin P., Raymond J.T., Evering W., Rebelatto M.C., Schenck E., Horvath C. Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies. Toxicol. Pathol. 2014;42(4):725-64.
  18. Koransky R., Ferastraoaru D., Jerschow E. Single nonsteroidal anti-inflammatory drug induced serum sickness-like reaction to naproxen in a patient able to tolerate both aspirin and ibuprofen. J. Allergy Clin. Immunol. Pract. 2016;4(1):160-61.
  19. Hanai S., Sato T., Takeda K., Nagatani K., Iwamoto M., Minota S. [Drug-Induced Lupus Caused by Long Term Minocycline Treatment for Acne Vulgaris]. Arerugi. 2015;64(9):1269-73.
  20. Rieder M.J. Immune mediation of hypersensitivity adverse drug reactions: implications for therapy. Expert. Opin. Drug. Saf. 2009;8(3):331-43.
  21. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301-5.
  22. Pichler W.J., Beeler A., Keller M., Lerch M., Posadas S., Schmid D., Spanou Z., Zawodniak A., Gerber B. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol. Int. 2006;55(1):17-25.
  23. Mallal S., Nolan D., Witt C., Masel G., Martin A.M., Moore C., Sayer D., Castley A., Mamotte C., Maxwell D., James I., Christiansen F.T. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727-32.
  24. Ostrov D.A., Grant B.J., Pompeu Y.A., Sidney J., Harndahl M., Southwood S., Oseroff C., Lu S., Jakoncic J., de Oliveira C.A., Yang L., Mei H., Shi L., Shabanowitz J., English A.M., Wriston A., Lucas A., Phillips E., Mallal S., Grey H.M., Sette A., Hunt D.F., Buus S., Peters B. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc. Natl. Acad. Sci. U S A. 2012;109(25):9959-64.
  25. Jenkins C., Costello J., Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004;328(7437):434.
  26. Sanchez-Borges M. NSAID hypersensitivity (respiratory, cutaneous, and generalized anaphylactic symptoms). Med. Clin. North. Am. 2010;94(4):853-64.
  27. Sanchez-Borges M., Capriles-Behrens E., Caballero-Fonseca F. Hypersensitivity to nonsteroidal anti-inflammatory drugs in childhood. Pediatr. Allergy Immunol. 2004;15(4):376-80.
  28. Gomes E.R., Brockow K., Kuyucu S., Saretta F., Mori F., Blanca-Lopez N., Ott H., Atanaskovic-Markovic M., Kidon M., Caubet J.C., Terreehorst I. Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group. Allergy. 2016;71(2):149-61.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2017

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies